This article is more than 5 years old. Information may no longer be current.

VIDEO: DCB yields superior 3-year outcomes vs. angioplasty

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAS VEGAS — In this video, Prakash Krishnan, MD, presents 3-year data from the IN.PACT SFA Randomized Trial that show improved outcomes with a drug-coated balloon compared with percutaneous transluminal angioplasty for treatment of symptomatic femoropopliteal lesions

During an interview at VIVA 16, Krishnan reported that treatment with the DCB (IN.PACT Admiral, Medtronic) yielded superior primary patency at 3 years compared with angioplasty (69.5% vs. 45.1%; P < .001). The data show “an absolute risk reduction of restenosis of 24.4%, which is highly statistically significant,” Krishnan, director of endovascular interventions at The Mount Sinai Hospital Cardiac Catheterization Laboratory and professor of medicine – cardiology and radiology, said.

The new 3-year data prove that “the IN.PACT [DCB] is durable, safe and may become the primary therapy for the treatment of femoropopliteal disease,” Krishnan said.